MedTrace Logo

Study of UB-312 in Healthy Participants and Parkinson's Disease Patients

NCT04075318 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-03-06

Study results available
· View outcomes & findings →

Summary

This is a 44-week, randomized, placebo-controlled, double-blind, single-center, phase 1 clinical trial consisting of a dose-escalation Part A study in healthy participants, followed by a Part B in participants with Parkinson's disease with a selected doses from Part A.

Conditions

Interventions

BIOLOGICAL

UB-312

A synthetic peptide-based vaccine

BIOLOGICAL

Placebo

Matching placebo

Sponsors & Collaborators

  • Centre for Human Drug Research, Netherlands

    collaborator OTHER

  • Worldwide Clinical Trials

    collaborator OTHER

  • Vaxxinity, Inc.

    collaborator INDUSTRY

  • United Neuroscience Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Vaxxinity, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-29
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04075318 on ClinicalTrials.gov